Favipiravir-induced Liver Injury in Patients with Coronavirus Disease 2019
Open Access
- 15 April 2021
- journal article
- letter
- Published by Xia & He Publishing in Journal of Clinical and Translational Hepatology
- Vol. 000 (000), 000
- https://doi.org/10.14218/jcth.2021.00011
Abstract
No abstract availableThis publication has 6 references indexed in Scilit:
- AVIFAVIR for Treatment of Patients With Moderate Coronavirus Disease 2019 (COVID-19): Interim Results of a Phase II/III Multicenter Randomized Clinical TrialClinical Infectious Diseases, 2020
- Prioritization of Anti‐SARS‐Cov‐2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human PharmacokineticsClinical Pharmacology & Therapeutics, 2020
- Dose Rationale for Favipiravir Use in Patients Infected With SARS‐CoV‐2Clinical Pharmacology & Therapeutics, 2020
- Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019‐nCoV InfectionClinical Pharmacology & Therapeutics, 2020
- A review of the safety of favipiravir – a potential treatment in the COVID-19 pandemic?Journal of Virus Eradication, 2020
- Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control StudyEngineering, 2020